GAPDHP35

Across TCGA pan-cancer cohorts, GAPDHP35 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of GAPDHP35’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where GAPDHP35 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GAPDHP35 is over-expressed in tumor.

KIRC, COAD, and UCEC are the cancer types where GAPDHP35 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GAPDHP35 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	IV	+2.606	<.001	12	view →
COAD	All	II,III,IV	+1.023	<.001	7	view →
UCEC	All	All	+1.070	.002	6	view →
LUAD	All	All	+0.695	<.001	6	view →
BRCA	All	II,III,IV	+0.624	<.001	6	view →
LUSC	All	All	+1.535	<.001	5	view →
LIHC	All	All	+0.809	<.001	5	view →
THCA	Male	III,IV	+0.581	.027	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

GAPDHP35–KIRC

Open the KIRC breakdown →